Interventional Cardiology - CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Interventional Cardiologist's Perspective

Skip to main content

Featured Authorities on Interventional Cardiology

Deepak L. Bhatt

Deepak L. Bhatt, MD, MPH

Executive Director of Interventional Cardiovascular Programs

Brigham and Women’s Hospital Heart and Vascular Center

Professor of Medicine

Harvard Medical School
Boston, Massachusetts

Keith A.A. Fox, MBChB, FRCP, FMedSci

Keith A.A. Fox, MBChB, FRCP, FMedSci

Professor, University of Edinburgh

Department of Cardiovascular Medicine

Professor, University and Royal Infirmary

Edinburgh, United Kingdom

Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA

Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA

Associate Head, Division of Cardiology

St. Michael’s Hospital

Professor, Department of Medicine

University of Toronto
Toronto, Ontario

J. Wouter Jukema, MD, PhD, FESC, FACC MC

J. Wouter Jukema, MD, PhD, FESC, FACC MC

Professor of Cardiology

Netherlands Heart Foundation

Chairman, Leiden Vascular Medicine

Leiden University Medical Center (LUMC)

Leiden, Netherlands

Ulf Landmesser MD, FESC

Ulf Landmesser MD, FESC

Professor of Cardiology

Medical Director, Department of Cardiology

Charite University Hospital

Berlin, Germany

Paul Ridker, MD

Paul Ridker, MD

Eugene Braunwald Professor

Harvard Medical School

Division of Cardiovascular Medicine

Director, Center for Cardiovascular Disease Prevention

Brigham and Women’s Hospital

Boston, MA

Phillipe Gabriel Steg, MD

Phillipe Gabriel Steg, MD

Professor of Cardiology

Université Paris – Diderot, Sorbonne-Paris Cité

Professor, National Heart and Lung Institute

Imperial College, London, UK

Director, Coronary Care Unit

Hôpital Bichat

Paris, France

Professor Andreas Zeiher, MD

Prof. Andreas Zeiher, MD

Chairman of Medicine

Department of Cardiology, Angiology, and Nephrology

J. W. Goethe University

Frankfurt, Germany

ABOUT THIS PROGRAM
AND FACULTY DISCLOSURES

PCSK9-FOCUSED RESOURCES
and TRIALS

Latest Videos |view all videos

Showing 1 - 12 of 46 results

Previous| 1 | 2 | 3 | 4 |Next

How do you identify “progressing patients” with high CV risk in whom PCSK9 therapy represents a game-changing strategy?

How do you identify “progressing patients” with high CV risk in whom PCSK9 therapy represents a game-changing strategy?

In your interventional cardiology practice, which markers of risk, in the patient who has undergone a PCI, do you focus on to promote consideration for using a PCSK9 inhibitor?

In your interventional cardiology practice, which markers of risk, in the patient who has undergone a PCI, do you focus on to promote consideration for using a PCSK9 inhibitor?

Based on ODYSSEY Outcomes, which patients in an interventional cardiology practice do you believe will benefit most from PCSK9 inhibition?

Based on ODYSSEY Outcomes, which patients in an interventional cardiology practice do you believe will benefit most from PCSK9 inhibition?

With respect to patients with HeFH and homozygous FH who are challenged with lifelong CV disease risk burden due to genetic risk, what role do you believe PCSK9 inhibitors should play, especially in younger patient populations?

With respect to patients with HeFH and homozygous FH who are challenged with lifelong CV disease risk burden due to genetic risk, what role do you believe PCSK9 inhibitors should play, especially in younger patient populations?

From the view of an interventional cardiologist and a lipid medicine/atherosclerosis specialist, can you discuss what LDL-C thresholds vs. clinical burden/clinical history thresholds are important for patient selection for PCSK9-based risk reduction?

From the view of an interventional cardiologist and a lipid medicine/atherosclerosis specialist, can you discuss what LDL-C thresholds vs. clinical burden/clinical history thresholds are important for patient selection for PCSK9-based risk reduction?

From an interventional cardiology perspective, what did ODYSSEY Outcomes teach us about the large subgroup of diabetic patients who had ACS plus stent insertions?

From an interventional cardiology perspective, what did ODYSSEY Outcomes teach us about the large subgroup of diabetic patients who had ACS plus stent insertions?

What other markers, besides LDL-C levels, do you believe we should consider to refine CV risk stratification?

What other markers, besides LDL-C levels, do you believe we should consider to refine CV risk stratification?

IC and lipid specialists are challenged to maximize CV risk reduction in high-risk populations. How should they approach the 70 mg/dL LDL-C target identified in the AHA Guidelines, and when is the 30 mg/dL – 70 mg/dL even more desirable?

IC and lipid specialists are challenged to maximize CV risk reduction in high-risk populations. How should they approach the 70 mg/dL LDL-C target identified in the AHA Guidelines, and when is the 30 mg/dL – 70 mg/dL even more desirable?

If someone is more than 12 months out after an ACS event and currently has a stent, would you still consider them to be eligible for PCSK9 therapy to lower LDL-C and residual CV risk?

If someone is more than 12 months out after an ACS event and currently has a stent, would you still consider them to be eligible for PCSK9 therapy to lower LDL-C and residual CV risk?

Professor Bhatt, you presented the pharmacoeconomic “in trial” analysis for alirocumab based on the ODYSSEY Outcomes Trial. Can you discuss the clinical implications of your analysis, and how reduced costs for alirocumab will affect IC practice?

Professor Bhatt, you presented the pharmacoeconomic “in trial” analysis for alirocumab based on the ODYSSEY Outcomes Trial. Can you discuss the clinical implications of your analysis, and how reduced costs for alirocumab will affect IC practice?

Within the context of the ESC and U.S. guidelines for LDL-C reduction, which recommend 70 mg/dL as a threshold target, how should we view the cholesterol landscape between 20 mg/dL and 70 mg/dL in light of the ODYSSEY Outcomes Trial?

Within the context of the ESC and U.S. guidelines for LDL-C reduction, which recommend 70 mg/dL as a threshold target, how should we view the cholesterol landscape between 20 mg/dL and 70 mg/dL in light of the ODYSSEY Outcomes Trial?

Since the overwhelming majority of post-ACS patients in ODYSSEY Outcomes had PCI as part of their ACS management, what have we learned about the safety and efficacy of alirocumab in this stent-rich population of high-risk patients?

Since the overwhelming majority of post-ACS patients in ODYSSEY Outcomes had PCI as part of their ACS management, what have we learned about the safety and efficacy of alirocumab in this stent-rich population of high-risk patients?

Showing 1 - 12 of 46 results

Previous| 1 | 2 | 3 | 4 |Next